Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited and certain officers for alleged violations of federal securities laws during the Class Period from February 21, 2025, to August 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased or acquired Telix securities during the specified Class Period [2]. - The complaint alleges that the defendants made false and misleading statements regarding Telix's progress with prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit can review the complaint and are encouraged to contact the law firm for further information [4]. - A deadline of January 9, 2026, has been set for investors to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].
Bronstein, Gewirtz & Grossman LLC Urges Telix Pharmaceuticals Limited Investors to Act: Class Action Filed Alleging Investor Harm